Thalassemia major is a progressive disease. Modern therapy with transf
usions and iron chelation has greatly improved both the quality and le
ngth of thalassemics life. Nevertheless, progressive overload of iron
in the organs, hepatitis and other infections acquired randomly imply
the risk of mortality that increases with age. Bone marrow transplant
from an HLA identical donor (a possibility for about 45 %) represents
the onely form of radical cure of the disease. With the classification
of the classes of risk we know today that a thalassemic child has a c
hance to die from transplant 3 to 100 with probability of being cured
94 %. Thalassemics that receive the transplant at a more advanced stag
e of complications of the disease have a major risk of death due to th
e transplant of class 2 (14 % probability of death due to the transpla
nt against 83 % chance of being cured). Class 43 patients have 9 chanc
es out of 100 to die of transplant and 60 % probability of being cured
of thalassemia.